Related Experiment Video
Updated: Oct 4, 2025
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
Syngeneic murine glioblastoma models: reactionary immune changes and immunotherapy intervention outcomes
Vijay Letchuman1, Leonel Ampie1,2, Ashish H Shah1
11National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland; and.
Abstract:
Glioblastoma is the most common primary malignant brain neoplasm with dismal 10-year survival rates of < 1%. Despite promising preliminary results from several novel therapeutic agents, clinical responses have been modest due to several factors, including tumor heterogeneity, immunosuppressive tumor microenvironment, and treatment resistance. Novel immunotherapeutics have been developed to reverse tumor-induced immunosuppression in patients with glioblastomas. In order to recapitulate the tumor microenvironment, reliable in vivo syngeneic murine models are critical for the development of new targeted agents as these models demonstrate rapid tumor induction and reliable tumor growth over multiple generations. Despite the clear advantages of murine models, choosing an appropriate model from an immunological perspective can be difficult and have significant ramifications on the translatability of the results from murine to human trials. Herein, the authors reviewed the 4 most commonly used immunocompetent syngeneic murine glioma models (GL261 [C57BL/6], SB28 [C57BL/6], CT-2A [C57BL/6], and SMA-560 [VM/Dk]) and compared their strengths and weaknesses from an immunological standpoint.
Insights
Choosing the right immunocompetent syngeneic murine glioma model is crucial for glioblastoma research. This review compares four common models (GL261, SB28, CT-2A, SMA-560) to aid in selecting the most immunologically relevant option for developing new therapies.
Area of Science:
- Neuro-oncology
- Immunology
- Preclinical Cancer Research
Background:
- Glioblastoma has a <1% 10-year survival rate, necessitating new therapeutic strategies.
- Tumor heterogeneity, an immunosuppressive microenvironment, and treatment resistance limit current glioblastoma therapies.
- Novel immunotherapeutics aim to overcome tumor-induced immunosuppression in glioblastoma patients.
Purpose of the Study:
- To review and compare four common immunocompetent syngeneic murine glioma models for their immunological relevance.
- To guide the selection of appropriate models for preclinical glioblastoma research and therapeutic development.
- To highlight the strengths and weaknesses of GL261, SB28, CT-2A, and SMA-560 models.
Main Methods:
- Literature review of four widely used syngeneic murine glioma models: GL261 (C57BL/6), SB28 (C57BL/6), CT-2A (C57BL/6), and SMA-560 (VM/Dk).
- Comparative analysis of these models based on their immunological characteristics.
- Evaluation of their suitability for recapitulating the glioblastoma tumor microenvironment.
Main Results:
- Each model (GL261, SB28, CT-2A, SMA-560) possesses unique immunological properties.
- The choice of model significantly impacts the translatability of preclinical findings to human glioblastoma trials.
- Understanding model-specific immunological aspects is vital for effective drug development.
Conclusions:
- Selecting an appropriate syngeneic murine model is critical for advancing glioblastoma immunotherapy research.
- Immunological considerations are paramount when choosing between GL261, SB28, CT-2A, and SMA-560 models.
- Optimizing model selection enhances the potential for successful translation of novel glioblastoma treatments.
